If you go to linkedin and view the "people also viewed" of GC there are always some interesting names. At the top of the list is Martin Tolar, MD, PhD, Founder, President & CEO of Alzheon that has a promising drug for Alzheimer’s.

Their lead product, ALZ-801, is ready for Phase 3 in Alzheimer’s and has been granted fast track designation by the FDA

This is from one of their recent PR's

“We are seeing the emergence of new insights on how amyloid-targeted therapies can be optimized to treat Alzheimer’s disease,” said Dr. Jeffrey Cummings . “We now understand much more about the underlying pathogenesis of the disease, as well as the role of toxic amyloid oligomers in the cascade of Alzheimer’s, and the patient populations most likely to respond to amyloid-targeted therapies. By overlaying this new understanding of amyloid’s role in Alzheimer’s, we can revitalize our efforts to develop targeted therapies that are on the near-term horizon for bringing desperately needed treatment options to patients with this disease.”

If that name sounds familiar, it's because you've seen it here:
https://www.amarantus.com/about/alzheimers-di...ostics-sab